In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients : a 6-Year Survey
We conducted in vitro antimicrobial susceptibility testing of 267 Achromobacter isolates for 16 antibiotics from 2017 to 2022. The highest susceptibility was found for piperacillin-tazobactam (70%) and ceftazidime-avibactam (62%). Between 30% and 49% of strains were susceptible to tigecycline, ceftazidime, and meropenem. We applied species-specific Achromobacter xylosoxidans breakpoints for piperacillin-tazobactam, meropenem, and trimethoprim-sulfamethoxazole and EUCAST pharmacokinetic/pharmacodynamic (PK/PD) breakpoints for the others. A. xylosoxidans was the most frequently isolated species, followed by Achromobacter insuavis and Achromobacter ruhlandii.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 67(2023), 7 vom: 18. Juli, Seite e0037923 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Olbrecht, Margo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Achromobacter |
|---|
| Anmerkungen: |
Date Completed 17.07.2023 Date Revised 14.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/aac.00379-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35811926X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35811926X | ||
| 003 | DE-627 | ||
| 005 | 20231227131323.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/aac.00379-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM35811926X | ||
| 035 | |a (NLM)37310234 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Olbrecht, Margo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients |b a 6-Year Survey |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.07.2023 | ||
| 500 | |a Date Revised 14.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We conducted in vitro antimicrobial susceptibility testing of 267 Achromobacter isolates for 16 antibiotics from 2017 to 2022. The highest susceptibility was found for piperacillin-tazobactam (70%) and ceftazidime-avibactam (62%). Between 30% and 49% of strains were susceptible to tigecycline, ceftazidime, and meropenem. We applied species-specific Achromobacter xylosoxidans breakpoints for piperacillin-tazobactam, meropenem, and trimethoprim-sulfamethoxazole and EUCAST pharmacokinetic/pharmacodynamic (PK/PD) breakpoints for the others. A. xylosoxidans was the most frequently isolated species, followed by Achromobacter insuavis and Achromobacter ruhlandii | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Achromobacter | |
| 650 | 4 | |a antibiotic resistance | |
| 650 | 4 | |a cystic fibrosis | |
| 650 | 4 | |a in vitro susceptibility | |
| 650 | 7 | |a Meropenem |2 NLM | |
| 650 | 7 | |a FV9J3JU8B1 |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Piperacillin |2 NLM | |
| 650 | 7 | |a X00B0D5O0E |2 NLM | |
| 650 | 7 | |a Tazobactam |2 NLM | |
| 650 | 7 | |a SE10G96M8W |2 NLM | |
| 700 | 1 | |a Echahidi, Fedoua |e verfasserin |4 aut | |
| 700 | 1 | |a Piérard, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Peeters, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Vandamme, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Wybo, Ingrid |e verfasserin |4 aut | |
| 700 | 1 | |a Demuyser, Thomas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 67(2023), 7 vom: 18. Juli, Seite e0037923 |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2023 |g number:7 |g day:18 |g month:07 |g pages:e0037923 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/aac.00379-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2023 |e 7 |b 18 |c 07 |h e0037923 | ||